AmorSui, a cutting-edge personal protective equipment (PPE) brand committed to safeguarding both people and the planet, has announced a successful $3.5 million seed funding round. This investment will propel AmorSui’s…
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company specializing in novel small molecule therapeutics from its boron chemistry platform, has announced the adoption of a limited-duration stockholder rights plan. This…
AstraZeneca’s IMFINZI® (durvalumab) Approved in the US for Comprehensive Treatment of Resectable Non-Small Cell Lung Cancer AstraZeneca has announced that IMFINZI® (durvalumab), in combination with chemotherapy, has received approval from…
Agendia is pleased to announce that it has achieved certification from the European Union (EU) In Vitro Diagnostic Medical Device Regulation (IVDR) for three of its products: the MammaPrint® FFPE…
Incyte (Nasdaq: INCY) today reported positive results from the pivotal Phase 3 inMIND study, which evaluated the efficacy and safety of tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19-targeted monoclonal antibody,…
BioNTech SE (Nasdaq: BNTX) today revealed top-line results from their Phase 3 clinical trial evaluating a combined mRNA vaccine candidate against influenza and COVID-19 in healthy adults aged 18-64. This…
Audax Private Equity (“Audax”) announced today that it has entered into a definitive agreement to acquire the Clinical Services business of Avantor, Inc. (NYSE: AVTR) (“Clinical Services” or “the Company”).…
Oggi, Agendia ha annunciato di aver ricevuto la certificazione dell’Unione Europea (UE) In vitro Diagnostic Medical Device Regulation (IVDR) per tre dei suoi prodotti: MammaPrint® FFPE Microarray, BluePrint® FFPE Microarray…
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases influenced by protein growth factors, today announced…
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been conditionally approved in China for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have…
Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, has announced its financial results for the second quarter of 2024. “This quarter marks a groundbreaking milestone in Duchenne…
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, has announced its unaudited financial results and notable corporate developments for the second quarter of 2024. CEO Statement Ying…